Ebitda growth of 35-40% expected in Q4; FY22-23e Ebitda up 2-3%; stock may re-rate due to mkt share gains; TP raised to Rs 8,000
Factoring in higher volumes, we raise our FY22-FY23e Ebitda by 2-3%, which takes it 12-13% ahead of consensus.
We expect UltraTech Cement (UTCEM) to be the key beneficiary of likely strong demand revival over the next few years given its low clinker utilisation, diversified market mix and significant non-trade presence vs peers. Announced expansion of ~20mnte would drive strong volume growth and with strong OCF generation of >Rs 110 bn p.a., the company may further accelerate its growth plans. Costs/te could further reduce by Rs 100/te by FY24e (our estimate) led by various cost efficiencies and RoCE is likely to expand by ~400bps over FY21-23e. Factoring in higher volumes, we raise our FY22-FY23e Ebitda by 2-3%, which takes it 12-13% ahead of consensus.
We believe UTCEM may rerate (valuation discount vs SRCM may narrow to 10-12% vs historical average of 20-25%) as it continues to gain market share with improved profitability/ RoCEs. Hence, we raise our target multiple to 15x FY23E EV/E (earlier: 13x) and raise our target price to Rs 8,000/sh (earlier: Rs 6,700). Maintain Buy. Key risks: lower demand/pricing.
Company may post strong 35-40% y-o-y Ebitda growth in Q4FY21e (vs 25-30% y-o-y growth for industry) led by >25% y-o-y volume growth (vs ~20% y-o-y industry growth). Diversified market mix vis-à-vis peers allows UTCEM to trade-off price in one market (say gain market share in North/Central) and compensate it by better prices in another market (say South/West) and yet improve overall profitability.
Market share gains likely to continue for UTCEM given large unutilised capacities of acquired entities, especially in high-growth North and Central regions where many of its peers may be facing capacity constraints. UTCEM also has large non-trade exposure (~35%) and stands to benefit from likely pick-up in infrastructure spend and better urban housing demand. Non-trade volumes grew by a strong 40% q-o-q and 25% y-o-y, and RMC revenues too grew 43% q-o-q and 24% y-o-y, in Q3FY21. UTCEM is likely to operate at high effective utilisation of ~83% over FY22-23e and post 9-10% volume CAGR over FY20-FY23e vs our estimate of 6-7% industry volume CAGR.
Volume growth to remain strong beyond FY23E too: UTCEM’s plan to add ~20mnte capacities (~18% of domestic capacities) over the next 2-3 years in the high growth/utilisation markets of East, Central and North would ensure faster ramp-up and higher volume growth. Given that >70% of these expansions are brownfield with average capex of $60/te, these assets are expected to enjoy healthy RoCE of >15% (vs 11.5% in FY20).
UTCEM to become debt-free by end-FY22e and is likely to generate OCF of >Rs 110 bn p.a. This may allow the company to accelerate its growth via both organic/inorganic routes. Historically, acquisitions have been integral to UTCEM’s growth story with the company enjoying strong track record on turning around acquisitions. We expect UTCEM to post revenue, Ebitda and PAT CAGRs of 12%, 17% and 30% respectively over FY20-FY23e.